TransCode Therapeutics
RNAZ
1 hedge funds and large institutions have $477K invested in TransCode Therapeutics in 2023 Q2 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
438% more capital invested
Capital invested by funds: $88.6K → $477K (+$388K)
0% more ownership
Funds ownership: 0% → 0% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$977K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
-$25.6K |
| 2 |
SSWM
Sheets Smith Wealth Management
Winston-Salem,
North Carolina
|
-$20.3K |
| 3 |
OGC
One68 Global Capital
New York
|
-$10.2K |
| 4 |
State Street
Boston,
Massachusetts
|
-$7.12K |
| 5 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
-$6.77K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SM
1
Sabby Management
Miami Beach,
Florida
| $433K | +$977K | +5 | New |
|
2
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $31.4K | – | – | – |
|
|
TRCT
3
Tower Research Capital (TRC)
New York
| $11.7K | – | – | – |
|
4
Wells Fargo
San Francisco,
California
| $9 | – | – | – |
|
5
BlackRock
New York
| – | -$469 | – | – |
|
|
6
Geode Capital Management
Boston,
Massachusetts
| – | -$25.6K | – | – |
|
7
Goldman Sachs
New York
| – | -$4.44K | – | – |
|
|
OGC
8
One68 Global Capital
New York
| – | -$10.2K | – | – |
|
|
SC
9
Shay Capital
New York
| – | -$5.1K | – | – |
|
|
SSWM
10
Sheets Smith Wealth Management
Winston-Salem,
North Carolina
| – | -$20.3K | – | – |
|
|
11
State Street
Boston,
Massachusetts
| – | -$7.12K | – | – |
|
12
Two Sigma Investments
New York
| – | -$6.57K | – | – |
|
|
WAM
13
Warberg Asset Management
Winnetka,
Illinois
| – | -$6.77K | – | – |
|
RNAZ Hedge Fund Activity: Q2 2023 in Review
1 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in TransCode Therapeutics (RNAZ) for Q2 2023, worth a combined $477K — up 438% from $88.6K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new RNAZ positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Sabby Management, opening a new position worth an estimated $977K. The largest seller was Geode Capital Management, cutting an estimated $25.6K.
- 1 institutional investor held TransCode Therapeutics (RNAZ) as of Q2 2023, up from 0 in Q1 2023.
- Funds reported $477K of TransCode Therapeutics stock for Q2 2023, up 438% quarter-over-quarter.
- 1 fund opened new TransCode Therapeutics positions in Q2 2023 and 0 closed out, a net change of +1 holder.
- The largest TransCode Therapeutics buyer in Q2 2023 was Sabby Management, an estimated $977K added.
- The largest TransCode Therapeutics seller in Q2 2023 was Geode Capital Management, an estimated $25.6K sold.
Based on aggregated 13F filings for Q2 2023.